Navigation Links
SuperSonic Imagine Announces That Gordon Waldron Has Been Named Executive Vice President and CFO
Date:11/16/2010

AIX-EN-PROVENCE, France, Nov. 16, 2010 /PRNewswire/ -- SuperSonic Imagine, the innovative ultrasound medical imaging company, is pleased to announce Gordon Waldron has been named as Executive Vice President and CFO. As a member of the board of directors, he will be responsible for driving all of SuperSonic Imagine's key strategic and commercial partnerships as well as overseeing the company's financial development plan.

Prior to joining SuperSonic Imagine in September 2010, Mr. Waldron spent five years as CFO for the French biotech company Novexel where he raised 50 million euros in 2006, negotiated a preclinical license agreement which brought the company a 75 million euros upfront payment in 2008 and directed a trade sale process resulting in the acquisition of Novexel by AstraZeneca for cash consideration of approximately $500 million in 2009.

Before Novexel, he spent eight years as VP Finance with Synt:em (Nimes, France) where he raised 32 million euros in three financing rounds.

He also spent five years with Texas Instruments, first as Finance Director for a French subsidiary, then as Group Finance Manager (based in the UK) covering 17 entities and a distributor network for Texas Instruments Software in Europe, the Middle East and Africa.

Mr. Waldron started his career with Spie Batignolles at the Head Office near Paris before becoming a controller of the company's US subsidiaries based in Pittsburgh.

He graduated from Duke University (USA) in 1988 and has both American and British nationalities.

Mr. Waldron commented, "I am pleased to join such a high caliber group of people working in such an innovative environment. This mix has already produced some impressive R&D achievements as the company quickly differentiated itself through the creation of a software based ultrasound technology. The Aixplorer® MultiWave™ Ultrasound system not only offers exceptional image quality but also has the unique ability to provide tissue elasticity assessment which is fully reproducible and independent of the user's experience, skill and scanning technique. The next chapter will be to leverage this R&D excellence through commercial alliances and to extend applications for the Aixplorer platform from breast alone to multiple other organs."

SuperSonic Imagine Founder and CEO, Dr. Jacques Souquet (PhD.) remarked, "We have built a very strong management team at SuperSonic Imagine and having someone of Gordon's experience and stature enhances our capabilities. In today's global business environment and particularly in medical imaging, having the ability to drive strategic partnerships is critical. Gordon brings this and other know-how to the company and will be a great asset."

About SuperSonic Imagine:

Founded in 2005 and based in Aix-en-Provence, France, SuperSonic Imagine is an innovative, multinational medical imaging company dedicated to developing a revolutionary ultrasound system: the Aixplorer®. The system leverages a unique MultiWave™ technology that enables the user to detect, characterize and, in the future, treat palpable and non-palpable masses. Engineers from all over the world have joined the SuperSonic Imagine team and the company now has offices in Aix-en-Provence, Seattle, London and Munich. SuperSonic Imagine holds the exclusive rights to 25 international patients and submissions in diagnostic imaging and therapy applications that are solely owned and solely used by the company.

For further information about SuperSonic Imagine please visit our website: http://www.supersonicimagine.fr.   www.supersonicimagine.com


'/>"/>
SOURCE SuperSonic Imagine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  Dermata ... innovative products to treat a variety of dermatological ... lead compound DMT210, in a Phase 2 acne ... developed to downregulate the proinflammatory cytokines in the ... in acne rosacea. This clinical ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
(Date:1/19/2017)... ... 2017 , ... The CHP suggests that California drivers can avoid hydroplaning as ... and increasing the space between themselves and other vehicles, according to a January 3 ... R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today ... implement new sales and marketing strategies. Grover comes with a total of 15 years ... a half years as Executive Vice President of Direct Sales at Traeger® Wood Pellet ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for ... people know that popular cosmetic fillers can enhance earlobes and rejuvenate ... director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. ...
Breaking Medicine News(10 mins):